Source: CureToday articles
The addition of Erleada to ADT may provide less benefit in patients with metastatic castration-sensitive prostate cancer and fewer bone metastases.
Recent Content
- FDA Approves Zynyz Treatment Regimen for Advanced Anal Cancer
- Evidence Over Anecdotes: The Misuse of Vitamin A During Measles Outbreaks
- The Promise of Psilocybin-Assisted Therapy for Opioid Use Disorder
- FDA Grants Orphan Drug Designation to Oligonucleotide Therapeutic for Spinocerebellar Ataxia
- High LDL Cholesterol Associated With Earlier Progression in Synchronous Metastatic Colorectal Cancer
- Finding Comfort in Teddy Bears Throughout My Experience With CLL
- Efti Plus Keytruda With Chemo Shows High Response in NSCLC Subset
- Ventana MET RxDx Assay Receives FDA Approval as Companion Diagnostic in NSCLC
- AAN 2025: Patient Voices Key to Understanding Broader Benefits of Xywav in Sleep Disorders
- Considerations for RSV Vaccination During Pregnancy